Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00869258 · ClinicalTrials.gov registry record · Phase 2
Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00869258 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 32 participants.
The verdict
NCT00869258, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether an experimental drug combination consisting of Gemzar®, Taxotere®, and Xeloda®, (called GTX) when followed by radiation therapy plus low-dose Gemzar, is safe and effective in treating advanced pancreatic cancer and to study and enhance the utility of PET scans in the evaluation of patients with pancreatic cancer.
Interventions
- DRUG Gemcitabine, docetaxel, and capecitabine
- RADIATION Radiation therapy with gemzar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-06 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00869258
The ClinicalTrials.gov registry entry for NCT00869258 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine, docetaxel, and capecitabine is the first listed.
NCT00869258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00869258 about?
NCT00869258 is a clinical study titled "Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar". The purpose of this study is to determine whether an experimental drug combination consisting of Gemzar®, Taxotere®, and Xeloda®, (called GTX) when followed by radiation therapy plus low-dose Gemzar, is safe and effective in treating advanced pancreatic cancer and to study and enhance the utility of...
What is the current status of trial NCT00869258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2005-06. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00869258?
The interventions under investigation include: Gemcitabine, docetaxel, and capecitabine (DRUG), Radiation therapy with gemzar (RADIATION).
Who is sponsoring clinical trial NCT00869258?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.